What is the dosage of Gazyva?

Gazyva is available in 1 dosages, including 25 mg/ml Injection 40 ml

What does Gazyva treat?

Gazyva treats Lymphoid Leukemia and Follicular Lymphoma

What is Gazyva made of?

Gazyva contains obinutuzumab which is a CD20-directed Cytolytic Antibody

How is Gazyva administered?

Gazyva is administered as a Injectable

What is Gazyva mechanism of action?

Gazyva mechanism of action is CD20-directed Antibody Interactions

Gazyva

(obinutuzumab)

40 ML obinutuzumab 25 MG/ML Injection [Gazyva]

BLACK BOX WARNING

Dosage & administration

* Premedicate for infusion-related reactions and tumor lysis syndrome.
* Administer only as intravenous infusion. Do not administer as an intravenous push or bolus.
* The recommended dosage for chronic lymphocytic leukemia is 100 mg on day 1 and 900 mg on day 2 of Cycle 1, 1,000 mg on day 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2–6.
* The recommended dosage for follicular lymphoma is 1,000 mg on day 1, 8 and 15 of Cycle 1, 1,000 mg on day 1 of Cycles 2-6 or Cycles 2-8, and then 1,000 mg every 2 months for up to 2 years.

drug label

Gazyva prescribing information

Have more Gazyva questions?

Submit MSL Request

Learn More

Need to report a Gazyva issue?

ONLINE FORMReport adverse event

Learn More

samples

Request Gazyva samples

NOT PROVIDED BY BRANDView Online Sample Form

Learn More

prior authorization

Gazyva Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Patient Consent Form

Patient Consent Form - Spanish

Learn More

Benefits investigation

Gazyva Prescriber Service & Patient Consent Form

Gazyva Prescriber Service Form - Online Portal

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Gazyva Financial assistance options

Co-pay savings program

commercial only

Gazyva Prescriber Service & Patient Consent Form

Gazyva Prescriber Service Form - Online Portal

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Gazyva Prescriber Service & Patient Consent Form

Gazyva Prescriber Service Form - Online Portal

Genentech Patient Foundation Application Form (1/2)

Genentech Patient Foundation Application Form (2/2) - Patient Consent Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Gazyva Patient education

Getting started on Gazyva

NOT PROVIDED BY BRANDInstructions For Use: Untreated Follicular Lymphoma

NOT PROVIDED BY BRANDInstructions For Use: Relapsed/Refractory Follicular Lymphoma

NOT PROVIDED BY BRANDInstructions For Use: Untreated Chronic Lymphoid Leukemia